Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

被引:38
|
作者
Gamsjaeger, Sonja [1 ]
Buchinger, Birgit [1 ]
Zoehrer, Ruth [1 ]
Phipps, Roger [2 ]
Klaushofer, Klaus [1 ]
Paschalis, Eleftherios P. [1 ]
机构
[1] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, WGKK & AUVA Trauma Ctr Meidling, Dept Med 1, A-1140 Vienna, Austria
[2] Procter & Gamble Pharmaceut, Mason, OH USA
关键词
Teriparatide; Alendronate; Risedronate; Bone material properties; Fourier transform infrared imaging; Raman Microspectroscopy; Mineral maturity; Collagen cross-links; ILIAC CREST BIOPSIES; FTIR MICROSPECTROSCOPIC ANALYSIS; PARATHYROID-HORMONE; AMERICAN-SOCIETY; MINERAL DENSITY; TASK-FORCE; QUALITY; OSTEONECROSIS; JAW; HYDROXYAPATITE;
D O I
10.1016/j.bone.2011.08.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a direct bearing on crystallite shape and size), relative proteoglycan content (regulating mineralization commencement), and the ratio of two of the major enzymatic collagen cross-links (pyridinoline/divalent). Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment. Moreover differences between ALN and RIS treated patients at baseline in the collagen cross-link ratio were observed. Since tissue areas of similar tissue age were analyzed, these differences may not be attributed to differences in bone turnover. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1160 / 1165
页数:6
相关论文
共 50 条
  • [41] Effects of alfacalcidol and alendronate on bone in previously untreated postmenopausal women with osteopenia or osteoporosis: One year interim subgroup analysis of the alfa study
    Bock, O.
    Boerst, H.
    Runge, M.
    Armbrecht, G.
    Martus, P.
    Schacht, E.
    Hashimotos, J.
    Felsenberg, D.
    BONE, 2007, 40 (06) : S253 - S253
  • [42] Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously treated with an antiresorptive drug
    Ettinger, B
    San Martin, J
    Crans, GG
    Pavo, I
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S15 - S15
  • [43] Effects of treatment by alendronate on bone mass in postmenopausal osteoporotic woman with vertebral fractures
    Povoroznjuk, VV
    Bayandina, EI
    Nikonenko, PI
    Tatarchuk, TF
    Sheremet, OB
    Sirotinskaya, GI
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 1999, 32 (02): : 265 - 265
  • [44] Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
    McClung, Michael
    Recker, Robert
    Miller, Paul
    Fiske, Darrell
    Minkoff, Jerome
    Kriegman, Audrey
    Zhou, Wenchun
    Adera, Mathews
    Davis, Jenny
    BONE, 2007, 41 (01) : 122 - 128
  • [45] Effects of two years treatment with teriparatide on bone mineral density in women with postmenopausal osteoporosis previously treated with anti-resorptive agents
    Michaud, M.
    CAHIERS DE L ANNEE GERONTOLOGIQUE, 2010, 2 (03): : 159 - 162
  • [46] Differences in early dynamics of serum bone markers in women with postmenopausal osteoporosis treated by alendronate or risedronate.
    Carmina, E
    Di Fede, G
    Sferrazza, C
    Pandolfo, MC
    Vitale, G
    Napoli, N
    Villareal, R
    Rini, GB
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S263 - S263
  • [47] Effects of treatment by alendronate on bone mass in postmenopausal osteoporotic woman with vertebral fractures
    Povoroznjuk, VV
    Bayandina, EI
    Nikonenko, PI
    Tatarchuk, TF
    Sheremet, OB
    Sirotinskaya, GI
    BONE, 1999, 25 (01) : 165 - 165
  • [48] Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties
    Hassler, N.
    Gamsjaeger, S.
    Hofstetter, B.
    Brozek, W.
    Klaushofer, K.
    Paschalis, E. P.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (01) : 339 - 352
  • [49] Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties
    N. Hassler
    S. Gamsjaeger
    B. Hofstetter
    W. Brozek
    K. Klaushofer
    E. P. Paschalis
    Osteoporosis International, 2015, 26 : 339 - 352
  • [50] Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
    Ma, Yanfei L.
    Zeng, Qing Q.
    Chiang, Alan Y.
    Burr, David
    Li, Jiliang
    Dobnig, Harald
    Fahrleitner-Pammer, Astrid
    Michalska, Dana
    Marin, Fernando
    Pavo, Imre
    Stepan, Jan J.
    BONE, 2014, 59 : 139 - 147